Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Republic of Korea.
Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Republic of Korea; Department of Internal Medicine, National Health Insurance Service Medical Center, Ilsan Hospital, Goyang, Gyeonggi-do, Republic of Korea.
Endocr Pract. 2022 Apr;28(4):384-390. doi: 10.1016/j.eprac.2021.12.015. Epub 2022 Jan 26.
The prevalence of adrenal insufficiency (AI) is increasing with an increase in the elderly population. Steroid replacement therapy (SRT) is often required in patients with AI because of acute symptoms and complications. The long-term effects of SRT on kidney function have not been well elucidated.
Overall, 788 patients diagnosed with AI between 2010 and 2015 at Yonsei University Health System were retrospectively evaluated. SRT was defined when an equivalent dose of ≥5 mg/d of hydrocortisone was initiated within 30 days of AI diagnosis and maintained for >30 days. Those not included in the SRT group were identified as the no-SRT group. The primary outcome was 40% reduction in the estimated glomerular filtration rate compared with baseline sustained for ≥30 days or end-stage kidney disease development.
The mean age of was 63.1 ± 15.4 years, and 43.0% were men. The SRT group comprised 387 patients. During a median follow-up duration of 4.1 years, the primary outcome occurred in 118 (15.0%) patients. The outcome incidence rate was higher in the SRT group (4.61/100 patient-years) than in the no-SRT group (2.76/100 patient-years). When the subdistribution hazard ratio for kidney outcome was assessed with death as a competing risk, the risk was 67% higher in the SRT group than in the no-SRT group (subdistribution hazard ratio, 1.67; 95% confidence interval, 1.16-2.45; P = .006). This association was maintained with inverse probability of treatment weighting and adjustment for confounding variables.
Kidney function decline was more prominent in patients with AI who received SRT. Further prospective evaluations are needed to confirm these findings.
随着老年人口的增加,肾上腺功能不全(AI)的患病率正在上升。由于急性症状和并发症,AI 患者通常需要类固醇替代治疗(SRT)。SRT 对肾功能的长期影响尚未得到充分阐明。
回顾性评估了 2010 年至 2015 年在延世大学健康系统诊断为 AI 的 788 例患者。SRT 定义为在 AI 诊断后 30 天内启动等效剂量≥5mg/d 的氢化可的松,并维持>30 天。未纳入 SRT 组的患者被确定为非 SRT 组。主要结局是与基线相比,估计肾小球滤过率下降 40%,持续时间≥30 天或发展为终末期肾病。
患者的平均年龄为 63.1±15.4 岁,其中 43.0%为男性。SRT 组包括 387 例患者。在中位随访 4.1 年期间,118 例(15.0%)患者发生了主要结局。SRT 组的结局发生率(4.61/100 患者年)高于非 SRT 组(2.76/100 患者年)。当以死亡为竞争风险评估肾脏结局的亚分布风险比时,SRT 组的风险比非 SRT 组高 67%(亚分布风险比,1.67;95%置信区间,1.16-2.45;P=0.006)。在使用治疗反事实概率加权和调整混杂变量后,这种关联仍然存在。
接受 SRT 的 AI 患者肾功能下降更为明显。需要进一步的前瞻性评估来证实这些发现。